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RESUMO 
O herpesvírus murídeo tipo 4, MuHV-4, é um gama-herpesvírus e, enquanto tal, estabelece 
infecções latentes em tecidos linfóides. Durante a infecção latente, o genoma de MuHV-4 persiste 
sob a forma de um epissoma no núcleo das células latentemente infectadas, e várias proteínas 
são expressas, entre as quais a proteína ORF73. Além do seu papel putativo na manutenção do 
epissoma viral, ORF73 modula os factores de transcrição celulares NF-kB e MYC, através do 
recrutamento das proteínas celulares Elonguina C e Culina 5, o que leva à formação do complexo 
de ligase de ubiquitina EC5S
ORF73
 (ElonguinaC–Culina5–SOCS). O complexo EC5S
ORF73 
interage 
com p65/RelA, um dos membros da família NF-kB, promovendo a sua poli-ubiquitinação e, 
consequentemente, a sua degradação pelo proteossoma. O complexo EC5S
ORF73
 promove ainda a 
poli-ubiquitinação de MYC, o que resulta na estabilização desta proteína em vez da sua 
degradação, como se verifica para p65/RelA. Deste modo, ORF73 tem efeitos contrários sobre 
NF-kB e MYC, inibindo a actividade transcricional de NF-kB, mas activando a actividade 
transcricional de MYC. Recentemente, foi identificado um motivo na proteína ORF73, o motivo 
SOCS-box (resíduos 199–215), que é responsável pelo recrutamento das proteínas Elonguina C e 
Culina 5 e, consequentemente, pela formação do complexo EC5S
ORF73
. A delecção funcional do 
motivo SOCS-box de ORF73, originando a proteína mutante ORF73–SOCS, impede a proteína 
viral de mediar tanto a poli-ubiquitinação de p65/RelA como a poli-ubiquitinação de MYC, 
comprometendo simultaneamente a sua capacidade de inibir a actividade transcricional de NF-kB 
e de activar a actividade transcricional de MYC, embora o mutante ORF73–SOCS mantenha 
intacta a capacidade de se ligar a ambos os factores celulares. Esta mutação suprime ainda a 
expansão do vírus MuHV-4 em células B e impede a infecção persistente in vivo. No entanto, 
como a mutação do motivo SOCS-box impede ORF73 de inibir NF-kB e de activar MYC em 
simultâneo, não é possível distinguir, em termos de fenótipo de infecção latente, o fenótipo que é 
devido à inibição de NF-kB e o fenótipo que resulta da activação de MYC. Além disso, a 
possibilidade de ORF73 mediar a poli-ubiquitinação de outros alvos celulares, ainda não 
identificados, não deve ser excluída. Portanto, é importante identificar regiões da proteína ORF73 
cuja mutação permita segregar as suas funções modulatórias sobre os substratos celulares. A 
mutação dos motivos de ORF73 envolvidos na ligação a p65/RelA e a MYC constitui uma boa 
alternativa à mutação do motivo SOCS-box. Contudo, estes motivos de ligação ao substrato ainda 
não foram identificados, tendo sido apenas demonstrado que a região N-terminal de ORF73 
(resíduos 1–140) é indispensável para a interacção de ORF73 com p65/RelA e MYC. A 
identificação dos motivos de ligação ao substrato na proteína ORF73 será importante para, em 
futuras experiências, construir vírus recombinantes que sejam incapazes de interagir e, 
consequentemente, de modular a actividade transcricional de NF-kB e de MYC, em separado. 
Deste modo, será possível distinguir os efeitos da inibição de NF-kB dos efeitos da activação de 
MYC sobre o fenótipo de MuHV-4, durante a infecção latente.  
O principal objectivo deste projecto foi a identificação de resíduos de aminoácidos específicos 
na proteína ORF73 necessários para a sua ligação a MYC ou a p65/RelA. Para tal, quinze 
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proteínas ORF73 mutantes foram construídas, através de mutagénese por scanning de alanina na 
porção N-terminal de ORF73. Esta técnica consiste na substituição dos resíduos-alvo por resíduos 
de alanina, os quais permitem eliminar as cadeias laterais para além do carbono β, sem alterar a 
conformação da cadeia principal e sem impor efeitos electrostáticos extremos. A interacção dos 
mutantes de ORF73 com MYC e p65/RelA foi depois testada em experiências de co-
imunoprecipitação. Os mutantes que interagiram fracamente com estas proteínas celulares foram 
sujeitos a ensaios funcionais, de modo a confirmar a diminuição da sua capacidade de modular 
MYC ou NF-kB. Deste modo, realizaram-se ensaios de gene repórter para testar se a perda de 
ligação de ORF73 a MYC ou a p65/RelA resultou na abolição da sua acção modulatória sobre a 
actividade transcricional destes factores celulares, e ainda ensaios de poli-ubiquitinação para 
investigar se essa perda de ligação se traduziu na perda da actividade de ligase de ubiquitina de 
ORF73. A capacidade destes mutantes para recrutarem os componentes do complexo EC5S
ORF73 
também foi avaliada, através de experiências de co-imunoprecipitação com as proteínas Elonguina 
C e Culina 5. 
As experiências de co-imunoprecipitação com MYC ou p65/RelA e os mutantes de ORF73 
que foram construídos permitiram identificar dois mutantes com uma capacidade comprometida 
para interagirem com estes factores celulares. O mutante ORF73141KKY143, com os resíduos 
141KKY143 substituídos por alaninas, demonstrou uma severa diminuição na sua capacidade de 
interagir com MYC e p65/RelA, sugerindo que os resíduos 141KKY143 são importantes para a 
ligação de ORF73 a MYC e a p65/RelA. Por outro lado, o mutante ORF73138PLP140, com os 
resíduos 138PLP140 substituídos por alaninas, revelou uma diminuição parcial da sua capacidade de 
interagir com MYC, tendo permanecido intacta a sua capacidade de interagir com p65/RelA, o que 
indica que os resíduos 138PLP140 têm um papel na ligação de ORF73 a MYC, mas não na ligação a 
p65/RelA. Contudo, os mutantes ORF73141KKY143 e ORF73138PLP140 comportaram-se da mesma 
forma nos ensaios de gene repórter, sendo incapazes de activar a actividade transcricional de 
MYC e apresentando uma diminuição parcial do seu efeito inibitório sobre NF-kB, o que indica que 
tanto a mutação dos resíduos 141KKY143 como a mutação dos resíduos 138PLP140 afectam a acção 
modulatória de ORF73 sobre MYC e sobre NF-kB. Os resultados dos ensaios de poli-ubiquitinação 
mostraram estar de acordo com as observações dos ensaios de gene repórter, uma vez que 
ambos os mutantes foram incapazes de promover a poli-ubiquitinação de MYC e de p65/RelA, 
reforçando a ideia de que os resíduos 141KKY143 e 138PLP140 são importantes para a modulação de 
MYC e de NF-kB pela proteína ORF73. De seguida, a capacidade dos mutantes ORF73141KKY143 
e ORF73138PLP140 para recrutarem a Elonguina C e a Culina 5, componentes do complexo 
EC5S
ORF73
,
 
foi avaliada através de experiências de co-imunoprecipitação. Ambos os mutantes 
recrutaram a Culina 5, mas foram incapazes de recrutar a Elonguina C, comprometendo assim a 
formação do complexo EC5S
ORF73
 e, consequentemente, suprimindo a função de ligase de 
ubiquitina de ORF73.  
O facto de os mutantes ORF73141KKY143 e ORF73138PLP140 não conseguirem recrutar a 
Elonguina C, embora não tivessem mutações no motivo SOCS-box, sugere que as mutações 
introduzidas nos resíduos 141KKY143 e 138PLP140 tiveram um impacto severo na estrutura 
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tridimensional de ORF73, possivelmente afectando outras funções da proteína viral, como o seu 
papel putativo na manutenção do epissoma. Este trabalho demonstrou ainda que a actividade de 
ligase de ubiquitina dos mutantes ORF73141KKY143 e ORF73138PLP140 estava comprometida, à 
semelhança do que se verificou com o mutante ORF73–SOCS, acima referido. Deste modo, não 
será possível clarificar, através da utilização destes mutantes em estudos in vivo, a contribuição 
independente da activação de MYC e da inibição de NF-kB pela proteína viral ORF73, durante a 
infecção latente de MuHV-4. Portanto, é necessário desenvolver outras estratégias para identificar 
os motivos de ligação de ORF73 a MYC e a p65/RelA, de modo a tornar possível a construção de 
mutantes de ORF73 que sejam incapazes de modular cada uma destas proteínas celulares 
separadamente. A resolução da estrutura tridimensional de ORF73, através de técnicas de 
cristalografia, pode dar um importante contributo para estes estudos.  
 
 
 
Palavras-chave: ORF73, NF-kB, MYC, motivo de ligação ao substrato, mutagénese por scanning 
de alanina.  
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ABSTRACT  
Murid herpesvirus-4 (MuHV-4) establishes latent infections in lymphoid tissues. During 
latency, ORF73 protein is expressed. ORF73 modulates the cellular transcription factors NF-kB 
and MYC, by assembling an EC5S
ORF73
 (ElonginC-Cullin5-SOCS) ubiquitin-ligase complex. 
EC5S
ORF73 
interacts with NF-kB family member p65/RelA, promoting its poly-ubiquitination and 
subsequent proteasomal degradation. EC5S
ORF73 
also mediates MYC poly-ubiquitination, but this 
promotes MYC stabilization. Thus, ORF73 inhibits NF-kB whereas it activates MYC transcriptional 
activity. SOCS-box motif in ORF73 recruits ElonginC and Cullin5, assembling EC5S
ORF73 
complex. 
However, the motifs of ORF73 involved in binding to p65/RelA and MYC are unidentified. 
Identification of ORF73 substrate-binding motifs is important to segregate NF-kB inhibition effects 
from MYC activation effects in MuHV-4 phenotype, during latency.  
The aim of this project was to identify specific amino acid residues, within N-terminus of 
ORF73, required for binding to MYC and p65/RelA. To this end, fifteen ORF73 mutants were 
generated by alanine-scanning mutagenesis, and tested on their ability to interact with those 
cellular substrates. ORF73141KKY143 mutant showed impaired ability to interact with MYC and 
p65/RelA, while ORF73138PLP140 mutant exhibited partially impaired ability to interact with MYC 
and intact ability to interact with p65/RelA. ORF73141KKY143 and ORF73138PLP140 mutants were 
unable to activate MYC transcriptional activity, had partially impaired inhibitory effect upon NF-kB, 
and were unable to promote MYC and p65/RelA poly-ubiquitination. Both mutants recruited Cullin5, 
but were unable to recruit ElonginC, thereby compromising the assembly of EC5S
ORF73
 complex 
and consequently preventing ORF73 to function as an ubiquitin-ligase. This suggested that 
mutations at 141KKY143 and 138PLP140 residues had severe consequences in ORF73 three 
dimensional structure, possibly affecting several of its functions.  
Altogether, this work showed that ORF73141KKY143 and ORF73138PLP140 mutants are not 
useful to study the biological role of ORF73 modulatory function towards MYC and NF-kB. Hence, 
other strategies must be developed to identify MYC and p65/RelA binding motifs in ORF73.  
 
 
 
Keywords: ORF73, NF-kB, MYC, substrate-binding motif, alanine-scanning mutagenesis. 
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ABBREVIATIONS  
Cul5  Cullin5 
DMEM   Dulbecco’s modified Eagle’s medium 
EBNA1  Epstein-Barr virus nuclear antigen 1 
EBV   Epstein-Barr virus  
ECS
 
 ElonginC–Culllin2/5–SOCS-box ubiquitin-ligase complex 
EloC  ElonginC 
FBS   Foetal bovine serum 
GC  Germinal centre 
HCMV   Human cytomegalovirus  
HEK   Human embryonic kidney 
HHV-6  Human herpesvirus-6 
HHV-7   Human herpesvirus-7 
HHV-8  Human herpesvirus-8 
HSV-1  Herpes simplex virus-1 
HSV-2  Herpes simplex virus-2 
IKK   IkB kinase 
KSHV   Kaposi’s sarcoma-associated herpesvirus 
LANA   Latency-associated nuclear antigen  
MuHV-4 Murid herpesvirus-4 
NF-kB  Nuclear factor-kappa B 
Ni-NTA  Nickel-nitrilotriacetic acid 
NLS   Nuclear localisation signal 
PBS   Phosphate buffered saline 
SCF  Skp1–Cullin1–F-box ubiquitin-ligase complex 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
SOCS  Suppressors of cytokine signalling 
TNF   Tumor necrosis factor 
VZV   Varicella-zoster virus  
wtORF73 Wild-type ORF73 
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1. INTRODUCTION  
1.1. Herpesviruses 
Herpesviridae is a family of enveloped viruses that have large double-stranded DNA genomes 
(>100 kb) with a vast coding capacity. Herpesviruses have biphasic life cycles that consist of a lytic 
and a latent phase; to achieve this, they have alternative programs of gene expression. During 
latency, only a limited subset of genes is expressed and viral particles are not produced. Thus, the 
virus escapes the host immune control and maintains its genome in the infected cells (Wu et al., 
2010). In fact, the hallmark of herpesvirus infections is the establishment of lifelong latent infections 
that can reactivate, causing one or more rounds of disease (Flint et al., 2004). Herpesviruses 
account for many persistent mammalian infections, and they are well adapted to their hosts, as 
demonstrated by their high human infection rates in most populations. Although many herpesvirus 
infections are asymptomatic or cause a mild illness, they can be devastating in 
immunocompromised hosts (Wu et al., 2010). 
The family Herpesviridae is divided into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae (Flint et al., 2004). Alpha-herpesviruses establish 
latency mainly in neurons, beta-herpesviruses in monocytes, and gamma-herpesviruses in 
lymphocytes (Stevenson et al., 2009). Humans are the natural hosts of eight herpesviruses: herpes 
simplex virus (HSV)-1, HSV-2, and varicella-zoster virus (VZV) (Alphaherpesvirinae); human 
cytomegalovirus (HCMV), human herpesvirus (HHV)-6, and HHV-7 (Betaherpesvirinae); Epstein-
Barr virus (EBV), and Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as HHV-8 
(Gammaherpesvirinae) (Flint et al., 2004; Wu et al., 2010). 
1.1.1. Gamma-herpesviruses  
Gamma-herpesviruses infect a variety of mammalian species, from mice to man. However, 
each gamma-herpesvirus is host-range specific. These viruses establish latent infections within 
lymphocytes, induce lymphoproliferative disease and are associated with a variety of lymphoid and 
non-lymphoid cell tumours (Nash et al., 2001; Simas & Efstathiou, 1998). 
Gamma-herpesviruses are divided into gamma-1-herpesviruses and gamma-2-herpesviruses, 
according to their genomic organization and gene content. EBV belongs to the gamma-1 subgroup 
(Simas & Efstathiou, 1998), while KSHV is included in the gamma-2 subgroup (Chang et al., 1994). 
 
 
1.2. Kaposi’s sarcoma-associated herpesvirus  
KSHV infection is uncommon (~3%) in Western countries, but it has a high prevalence 
(ranging from 20 to 80%) in sub-Saharan Africa (Dedicoat & Newton, 2003). KSHV has an etiologic 
role in Kaposi’s sarcoma, and also in primary effusion lymphoma and multicentric Castleman’s 
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disease (Chang et al., 1994; Jones et al., 1998; Soulier, et al., 1995). Although Kaposi’s sarcoma 
has low malignant potential in immunocompetent individuals, it can be lethal in 
immunocompromised hosts (Verma & Robertson, 2003) and it has become one of the most 
common AIDS malignancies worldwide (Cai et al., 2010; Wu et al., 2010). Therefore, it is essential 
to understand the mechanisms by which KSHV induces cellular proliferation, evades immune-
mediated clearance and maintains viral genome during latency, in order to develop strategies that 
allow the control of KSHV-associated tumorigenesis.  
1.2.1. KSHV latency-associated protein 
During latent infection, KSHV expresses a latency-associated nuclear antigen (LANA or 
ORF73) (Dupin et al., 1999). KSHV genome persists as a multicopy, non-integrated, circular form 
(episome), in the nucleus of latently infected cells. LANA mediates episome persistence by 
tethering viral genomes to mitotic chromosomes, which allows the segregation of viral DNA to 
daughter nuclei, and thus episome persistence in proliferating cells (Ballestas et al., 1999; Decker 
et al., 1996). Furthermore, LANA also regulates transcription and cell growth through interactions 
with cellular proteins, including through E3 ubiquitin-ligase activity, which enables it to mediate the 
poly-ubiquitination of cellular targets, namely VHL and p53 proteins (Cai et al., 2006). 
1.2.2. Pathogenesis studies  
In spite of the progress in molecular virology of KSHV, many aspects of its in vivo biology 
remain unknown. This is due to the fact that KSHV is a species-specific virus, so it does not infect 
laboratory mice or rats, limiting in vivo pathogenesis studies (Nash et al., 2001). For this reason, 
research has been done on the development of animal model systems to investigate the 
pathogenesis of KSHV infection. Infection of laboratory mice with murid herpesvirus-4 (MuHV-4) 
has proved to be a good model system (Simas & Efstathiou, 1998).  
 
 
1.3. Murid herpesvirus-4 
Murid herpesvirus-4 (MuHV-4; archetypal strain MHV-68) was originally isolated from bank 
voles (Clethrionomys glariolus) in Slovakia (Blaskovic et al., 1980), and it is widespread among 
rodent populations in Northern Europe (Simas & Efstathiou, 1998). MuHV-4, like KSHV, is a 
gamma-2-herpesvirus. Its genome consists of 118 kb of unique sequence DNA with a G+C content 
of 46%, flanked by a variable number of 1,2 kb terminal repeat regions (Efstathiou et al., 1990). It is 
estimated that MuHV-4 genome contains approximately 80 protein-coding open reading frames 
(ORFs), the majority of which are collinear and homologous to those of other 
gammaherpesviruses, namely KSHV (Virgin et al., 1997). Besides, several MuHV-4 genes are 
functionally homologous to cellular genes (Nash et al., 2001).  
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MuHV-4 establishes a lifelong latent infection in lymphoid tissues (Sunil-Chandra et al., 1992) 
and, like KSHV, its genome persists as a multicopy episome in latently infected cells. Latency is 
established predominantly in B cells (Marques et al., 2003), but can also be established in 
macrophages, dendritic cells and epithelial cells (Flaño et al., 2000; Stewart et al., 1998). MuHV-4 
induces proliferation of latently infected B cells in germinal centre (GC)-like reactions, which allows 
the virus to gain access to the long-lived memory B cell pool, the major reservoir of MuHV-4 
latency (Flaño et al., 2002; Stevenson, 2004; Stevenson et al., 2009).  
1.3.1. MuHV-4 latency-associated protein  
MuHV-4, like KSHV, encodes a latency-associated protein, which is the product of ORF73 
gene. ORF73 protein of MuHV-4, with 314 amino acid residues, is homologous in sequence and 
function to ORF73 protein of KSHV (LANA) (Fowler et al., 2003). To easily distinguish these two 
proteins throughout this thesis, ORF73 of KSHV will be named LANA, while ORF73 of MuHV-4 will 
be simply denominated ORF73.  
It has been shown that ORF73 is required for the establishment and maintenance of latency, 
particularly for in vitro maintenance of viral episome (Fowler et al., 2003). In addition, recent studies 
have shown that ORF73 regulates cellular transcription by modulating the cellular transcription 
factors NF-kB (Rodrigues et al., 2009) and MYC (Rodrigues et al., unpublished data). ORF73, like 
LANA, has E3 ubiquitin-ligase activity, promoting the poly-ubiquitination of cellular substrates and 
interfering with their turnover. The mechanisms by which ORF73 modulates NF-kB and MYC are 
described below.  
Since ORF73 and LANA are functionally homologous, particularly in episome maintenance 
and E3 ubiquitin-ligase functions, and an excellent murine model of MuHV-4 latency exists (Simas 
& Efstathiou, 1998), ORF73 provides a potential model to investigate LANA in vivo. Moreover, 
recombinant genetics for MuHV-4 is robust and allows ready introduction of ORF73 mutations.  
1.3.1.1. Modulation of the NF-kB family member p65/RelA by ORF73 
Nuclear factor-kappa B (NF-kB) is a family of ubiquitously expressed transcription factors. In 
mammalian cells, the NF-kB family comprises five members: p65/RelA, RelB, c-Rel, p105/p50 and 
p100/p52 (Blank et al., 1992). NF-kB family members can form homo- or heterodimers (Saccani et 
al., 2003) and bind to specific DNA sequences (kB sites) in the promoter region of a variety of 
genes, thereby modulating their transcription. NF-kB target genes are involved in critical biological 
functions, including immune response, inflammation, apoptosis, cell proliferation and differentiation 
(Baldwin, 2001; Ghosh et al., 1998). Deregulation of NF-kB signalling is associated with 
oncogenesis and cancer malignancies (Karin et al., 2002). 
Under homoeostasis, NF-kB dimers are normally sequestered in the cytoplasm by the 
inhibitory IkB proteins. These proteins bind to NF-kB and mask its nuclear localization signal, 
thereby preventing nuclear uptake of NF-kB. In the presence of an extracellular stimulus, such as 
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tumor necrosis factor (TNF), an IkB kinase (IKK) complex is activated. IKK phosphorylates IkB 
molecules, leading to their poly-ubiquitination and proteasomal degradation. Free NF-kB is then 
translocated to the nucleus, where it binds to kB sites in DNA, activating target gene transcription 
(Karin & Ben-Neriah, 2000). 
However, once the stimulus stops, NF-kB activity must be terminated. De novo expression of 
IkB molecules, whose genes are themselves NF-kB target genes, allows resynthesised IkB to enter 
the nucleus and to dissociate NF-kB dimers from kB sites, transporting NF-kB back to cytoplasm 
(Arenzana-Seisdedos et al., 1997). Furthermore, NF-kB activity can also be terminated through 
direct poly-ubiquitination and subsequent proteasomal degradation of promoter-bound p65/RelA 
(Saccani et al., 2004). This mechanism is regulated through the activation of E3 ubiquitin-ligase 
proteins, which accept ubiquitin from E2 ubiquitin-conjugating enzymes, and transfer it to the target 
protein (Weissman, 2001). The addition of successive molecules of ubiquitin to p65/RelA leads to 
its poly-ubiquitination; poly-ubiquitinated p65/RelA is then degraded by the proteasome. 
Traditionally, poly-ubiquitination has been viewed as a mechanism that targets proteins for 
degradation by the proteasome (Hershko & Ciechanover, 1998); however, it has been shown that 
poly-ubiquitination can also enhance the stability of target proteins (Popov et el., 2010), as will be 
described for MYC further on. The outcome of poly-ubiquitination depends on the kind of linkage 
between the individual ubiquitin molecules in a poly-ubiquitin chain. 
E3 ubiquitin-ligase proteins are multisubunit complexes. The ECS
SOCS1
 (ElonginC–Culllin2/5–
SOCS [suppressors of cytokine signalling]-box) E3 ubiquitin-ligase complex has been implicated in 
the poly-ubiquitination of p65/RelA (Ryo et al., 2003). In this complex, ElonginC bridges the 
scaffold proteins Cullin2 or Cullin5 to the SOCS-box-containing adaptor protein, the SOCS1 protein 
(Cai et al., 2006; Kamura et al., 2001; Kamura et al., 2004), which functions as the substrate 
recognition component of the ECS
SOCS1
 complex. Recently, it has been shown that the ORF73 viral 
protein has a SOCS-box motif (amino acid residues 199-215), which allows it to recruit ElonginC 
and Cullin5, thereby assembling an EC5S
ORF73
 (ElonginC–Culllin5–SOCS-box) ubiquitin-ligase 
complex (Rodrigues et al., 2009).  EC5S
ORF73 
interacts with nuclear p65/RelA, promoting its poly-
ubiquitination and subsequent proteasomal-dependent degradation, which in turn results in a 
strong termination of NF-kB activity. Therefore, ORF73 has an inhibitory effect upon NF-kB by 
promoting p65/RelA degradation. 
1.3.1.2. Modulation of MYC by ORF73  
MYC proteins include c-MYC, N-MYC and L-MYC, and are encoded by the MYC-family proto-
oncogenes (Adhikary & Eilers, 2005; Eilers & Eisenman, 2008). MYC is essential in normal cell 
proliferation, growth, survival and differentiation. However, its deregulation can originate an 
enlarged pool of proliferating, self-renewing cells, which are vulnerable to further oncogenic events 
that accelerate tumorigenesis (Larsson & Henriksson, 2010). MYC is a global transcriptional 
regulator: it binds to approximately 10–15% of the genome and it can both activate and repress 
cellular transcription. Furthermore, MYC must form a heterodimer with Max in order to bind to DNA. 
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MYC-Max heterodimers bind to a consensus sequence (CACGTG), known as E-box (Meyer & 
Penn, 2008). 
MYC is tightly regulated both at the transcriptional and post-transcriptional levels, including 
through poly-ubiquitination. It has been shown that the SCF
β-TrCP
 (Skp1–Cullin1–F-box) E3 
ubiquitin-ligase complex mediates MYC poly-ubiquitination, thereby regulating its turnover. 
However, SCF
β-TrCP
-mediated poly-ubiquitination enhances MYC stability, instead of targeting it to 
proteasomal degradation (Popov et al., 2010). In SCF
β-TrCP 
complex, β-TrCP is the adaptor protein 
that recognises the substrate. Recent studies suggest that ORF73 acts like β-TrCP protein, binding 
to MYC and promoting its poly-ubiquitination and subsequent stabilization (Rodrigues et al., 
unpublished data). Thus, ORF73 activates MYC transcriptional activity, which is in contrast with its 
inhibitory effect upon NF-kB. ORF73-mediated MYC poly-ubiquitination, like p65/RelA poly-
ubiquitination, involves the recruitment of ElonginC and Cullin5, through ORF73 SOCS-box motif, 
in order to assemble the EC5S
ORF73
 ubiquitin-ligase complex.  
1.3.1.3. p65/RelA and MYC binding motifs in ORF73 
Rodrigues et al. have generated an ORF73 protein with four point mutations at its SOCS-box 
motif (ORF73-SOCS mutant), which result in disruption of SOCS-box and, consequently, in loss of 
ORF73 E3 ubiquitin-ligase activity (Rodrigues et al., 2009). In vivo studies with ORF73-SOCS 
mutant have shown that this functional deletion of SOCS-box motif in ORF73 abrogates its 
inhibitory effect upon NF-kB, suppresses MuHV-4 expansion in GC B cells, and prevents MuHV-4 
persistent infection in mice, suggesting that inhibition of NF-kB signalling by ORF73 is essential for 
MuHV-4 latency. Recently, it has been shown that functional deletion of SOCS-box motif in ORF73 
also abrogates its ability to activate MYC (Rodrigues et al., unpublished data). These findings 
indicate that mutations at SOCS-box disrupt not only the ability of ORF73 to terminate NF-kB 
activity, but also its ability to modulate MYC and even other possible cellular targets that remain to 
be identified. Therefore, mutations must be introduced at regions of ORF73 other than SOCS-box 
motif, in order to segregate the role of ORF73-mediated NF-kB inhibition and MYC activation in 
MuHV-4 latent infection, thereby clarifying the contribution of modulation of each transcription 
factor.  
ORF73 protein is the substrate recognition component of the EC5S
ORF73 
complex, which 
promotes the poly-ubiquitination of p65/RelA and MYC. Therefore, ORF73 must have a motif that 
allows it to bind to p65/RelA, and a motif that allows it to bind to MYC. Since it has been shown that 
the SOCS-box is not required for binding of ORF73 to p65/RelA (Rodrigues et al., 2009) or MYC 
(Rodrigues et al., unpublished data), it is predicted that there are distinct functional motifs in 
ORF73: a motif implicated in the recruitment of ElonginC and Cullin5 (SOCS-box), a motif involved 
in p65/RelA interaction (p65/RelA binding motif), and a motif involved in MYC interaction (MYC 
binding motif). However, p65/RelA and MYC binding motifs in ORF73 remain to be identified. 
These substrate binding motifs may be either linear (specific amino-acid sequence) or structural 
(small local arrangement of secondary structure elements which then coalesce to form domains) 
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(Petsko & Ringe, 2004). Recent studies have shown that ORF73 interacts with p65/RelA and MYC 
through its proline-rich N-terminal region (amino acid residues 1-140) (Rodrigues et al., 
unpublished data). If linear motifs are involved in substrate binding, and the motif involved in 
p65/RelA binding is different from the motif required for MYC binding, then the mutation of specific 
residues within the N-terminus of ORF73 will abrogate its ability to interact and modulate either 
p65/RelA or MYC, separately. This will allow the construction of recombinant MuHV-4 viruses, with 
either p65/RelA or MYC binding-deficient ORF73. Since recombinant viruses will have disrupted 
ability to modulate NF-kB or MYC, separately, the phenotype analysis of these viruses upon 
infection of mice will segregate the biological significance of termination of NF-kB activity and 
activation of MYC, promoted by ORF73. 
 
 
  
7 
 
2. OBJECTIVES  
The aim of this project was to identify specific amino acid residues within the N-terminus of 
ORF73 required for binding to p65/RelA or MYC. Identified motifs would be of extreme importance 
in future experiments, to construct recombinant viruses with disrupted ability to modulate NF-kB or 
MYC transcriptional activities, separately.  
To achieve this, ORF73 proteins with point mutations were generated by alanine-scanning 
mutagenesis, and then tested on their ability to interact with p65/RelA and MYC. Binding-deficient 
ORF73 mutants were further characterised by functional assays to confirm their impaired ability to 
act upon NF-kB or MYC. Thus, reporter gene assays were performed to test if loss of binding of 
ORF73 to p65/RelA or MYC abrogated its ability to modulate transcriptional activity of NF-kB or 
MYC. Furthermore, poly-ubiquitination assays were performed to assess if loss of binding of 
ORF73 to these cellular substrates prevented ORF73 to function as an E3 ubiquitin-ligase.  
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3. MATERIALS AND METHODS 
3.1. Plamids  
pCMV-Myc construct encoding wild-type ORF73 (wtORF73) (pCMV-Myc-ORF73) was 
previously described (Rodrigues et al., 2009). p65/RelA expression plasmid and pC45 plasmid 
containing kB consensus sequences that drive the expression of firefly luciferase (NF-kB reporter 
plasmid) were also earlier described (Anrather et al., 1999; Winkler et al., 1996). MYC expression 
plasmid was kindly provided by Neil Perkins. pMYC-TA-Luc plasmid with six tandem copies of the 
E-box consensus sequence driving the expression of firefly luciferase (MYC reporter plasmid) was 
purchased from Clontech. Renilla plasmid was a kind gift by Xosé R. Bustelo. Histidine-tagged 
ubiquitin plasmid (His6-Ubiq) was kindly offered by Dr. D. Bohmann. Flag-tagged ElonginC and 
Myc-tagged Cullin5 expression plasmids were kindly provided by Dr. E. Burstein and Dr. X.F. Yu, 
respectively.  
pCMV-Myc constructs encoding ORF7311TTS13, ORF7321KRR23, ORF7335RRR37, 
ORF7346PPP48, ORF7363PNP65, ORF7376TLP78, ORF7391PPS93, ORF73102SPD104, 
ORF73121PPP123, ORF73134NPS136, ORF73141KKY143, ORF73141K, ORF73142K, ORF73143Y, and 
ORF73138PLP140 mutants were generated by site-directed mutagenesis, using QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer’s instructions. The 
oligonucleotides designed to introduce alanine substitution mutations in pCMV-Myc-ORF73 
constructs are listed in Table 1. All constructs were verified by DNA sequencing.  
3.2. Immunological reagents 
Anti-ORF73 serum obtained from rabbit was previously described (Rodrigues et al., 2009). 
Anti-p65, anti-EloC and anti-Cul5 antibodies were purchased from Santa Cruz Biotechnology. 
Mouse antibodies directed to Myc, HA and Flag epitopes were from Clontech, Covance and Sigma, 
respectively. Actin was detected with a rabbit anti-actin polyclonal antibody (Sigma). Horseradish 
peroxidase-conjugated secondary antibodies were from Amersham Biosciences. The 
fluorochrome-labelled secondary antibody used in immunofluorescence analysis (Alexa 594 anti-
mouse) was from Jackson Immunoresearch. 
3.3. Cells and transfections 
Human embryonic kidney (HEK) 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 2 mM glutamine and 100 
U/ml penicillin–streptomycin. Transiently transfection of HEK 293T cells with plasmidic DNA was 
performed with Fugene 6 (Roche), according to the manufacturer’s instructions. In all transfections, 
an empty vector was used to normalise the total amount of plasmidic DNA.  
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3.4. Immunoprecipitations  
For co-immunoprecipitation experiments with MYC and ORF73 mutants, or with p65/RelA and 
ORF73 mutants, HEK 293T cells (3x10
6
) were transiently transfected with expression plasmids 
encoding MYC (2 µg) or p65/RelA (2 µg), and wild-type or the mutant versions of ORF73 described 
above (2 µg). After 48 h in culture, cells were rinsed in ice-cold phosphate buffered saline (PBS) 
and disrupted in 500 µl of ice-cold lysis buffer containing 10 mM Tris–HCl (pH 7.5), 150 mM NaCl, 
1% Triton X-100, 1 mM NaF, 100 mM Na3VO4 and a cocktail of protease inhibitors (Cϕmplete; 
Roche). Lysates were clarified by centrifugation, and incubated with 1 µg of antibodies to ORF73 
(anti-ORF73 serum) for 2 h at 4ºC. In p65/RelA experiments, lysates were precleared with protein 
G-conjugated Sepharose beads (GE Healthcare) for 1 h at 4ºC, prior to incubation with anti-ORF73 
serum. Immunecomplexes were recovered by incubation with protein G-conjugated Sepharose 
beads (50 µl/sample) for 1 h at 4ºC. After three washes with ice-cold lysis buffer, proteins were 
eluted in reducing Laemmli’s buffer, resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and immunoblotted with the appropriate 
antibodies. In addition, representative aliquots of the total cellular lysates, not subjected to 
immunoprecipitation, were used to detect appropriate expression of MYC or p65/RelA, ORF73, and 
actin. 
For co-immunoprecipitation experiments with ElonginC and ORF73 mutants, or with Cullin5 
and ORF73 mutants, HEK 293T cells (3x10
6
) were transiently transfected with expression plasmids 
encoding ElonginC (2 µg) or Cullin5 (4 µg), and wild-type or mutant versions of ORF73 (2 µg). After 
48 h in culture, cells were rinsed in ice-cold PBS and disrupted in 500 µl of ice-cold lysis buffer. 
Lysates were clarified by centrifugation and incubated with 1 µg of antibodies to either ElonginC or 
Cullin5 for 2 h at 4ºC. Immunecomplexes were recovered and processed as described above. 
Representative aliquots of the total cellular lysates, not subjected to immunoprecipitation, were 
used to detect appropriate expression of ElonginC or Cullin5, ORF73, and actin.  
3.5. Reporter gene assays 
For reporter gene assays with MYC, HEK 293T cells (2x10
5
) were transiently transfected with 
500 ng of a firefly luciferase reporter plasmid (pMYC-TA-Luc), 1 µg of ORF73 expression plasmid 
(either wild-type or mutant versions) and, in experiments with MYC overexpression, 1 µg of MYC 
expression plasmid. In all transfections, a Renilla luciferase expression plasmid (20 ng) was used 
to normalise luciferase values. After 48 h in culture, cells were washed in PBS and lysed in 200 µl 
of passive lysis buffer (Promega). Firefly luciferase and Renilla luciferase activities were assayed 
using beetle luciferin and coelenterazine (Promega), respectively. Light emission in each sample 
was quantified in a luminometer. Results are shown as the fold induction relative to luciferase 
activity measured in cells with endogenous levels of MYC that did not express ORF73. 
For reporter gene assays with p65/RelA, HEK 293T cells (2x10
5
) were transiently transfected 
with 150 ng of a firefly luciferase reporter plasmid (pC45) and 1 µg of ORF73 expression plasmid 
(either wild-type or mutant versions). A Renilla luciferase expression plasmid (20 ng) was used to 
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normalise luciferase values. After 48 h in culture, cells were left unstimulated or stimulated with 
TNF-α (50 ng/ml) for 7 h. Cells were washed in PBS and lysed in 200 µl of passive lysis buffer. 
Firefly luciferase and Renilla luciferase activities were assayed as described above. Results are 
shown as the fold induction relative to luciferase activity measured in unstimulated cells. 
In all reporter gene assays, representative aliquots of the total cellular lysates were used to 
detect appropriate expression of ORF73. 
3.6. Immunofluorescence analysis 
HEK 293T cells grown on poly-L-lysine-coated coverslips were transiently transfected with 1 
µg of ORF73 expression plasmid (either wild-type or mutant versions). After 24 h, cells were 
washed in PBS and incubated in fixative solution (2% sucrose and 5% formaldehyde in PBS) for 20 
min. After three washes in PBS, cells were permeabilised (0.1% Triton X-100 in PBS) for 15 min, 
and then washed once in PBS. Immunostaining was performed with the appropriate antibodies 
diluted in PBS. DNA was stained with DAPI solution (5 µg/ml) to visualise the nucleus. Following 
staining, cells were fixed again in fixative solution for 5 min. After three washes in PBS, coverslips 
were rinsed in distilled water and mounted onto microscope slides with Mowiol. 
3.7. Poly-ubiquitination assays 
Levels of ubiquitinated overexpressed MYC or p65/RelA were determined by pull-down of 
histidine-tagged ubiquitin (His6–ubiquitin) with nickel-nitrilotriacetic acid (Ni-NTA) agarose beads 
(Qiagen). HEK 293T cells (3x10
6
) were transfected with expression plasmids encoding MYC (3 µg) 
or p65/RelA (3 µg), wild-type or mutant versions of ORF73 (3 µg), and His6–ubiquitin (3 µg). After 
48 h in culture, cells were rinsed in ice-cold PBS and lysed in 750 µl of ice-cold urea buffer 
containing 8 M urea, 50 mM Tris–HCl (pH 7.5), 300 mM NaCl, 1% Triton X-100, 10 mM imidazole, 
1 mM Na3VO4 and a cocktail of protease inhibitors (Cϕmplete; Roche). Lysates were clarified by 
centrifugation and incubated with Ni-NTA beads (50 µl/sample) for 3 h at 4ºC. After incubation, 
beads were collected by centrifugation and washed three times with urea buffer. Proteins were 
eluted and denatured by boiling in Laemmli’s buffer, resolved by SDS-PAGE, transferred to 
nitrocellulose, and immunoblotted with the appropriate antibodies. In addition, representative 
aliquots of the total cellular lysates, not subjected to Ni-NTA pull-down, were used to detect 
appropriate expression of MYC or p65/RelA, and ORF73. 
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Mutant 
a
 Primer sequence 
ORF7311TTS13 CACCGACTACACGCAACGCAGCCGCAGGCAAAACCAGATCA 
ORF7321KRR23 CAGGCAAAACCAGATCAGGGTGCGCAGCTGCGTGCTTCAACAAACCAGCAGCCA 
ORF7335RRR37 AACAAACCAGCAGCCATGCCTCCTAAAGCAGCCGCCGCTCCAAAAAGACCAG 
ORF7346PPP48 GACCAGCCCCTCCTGCAGCAGCGGGATGCC 
ORF7363PNP65 CCAGGGAACTCAAACGGCAGCCGCCCCATCACCACCAGT 
ORF7376TLP78 TGCCCCCTTCATCACCAGCAGCTGCCTCATCCCCCGTCC 
ORF7391PPS93 CACCAGTACATGAGGCAGCAGCTCCTTCCCCCCCA 
ORF73102SPD104 CCCCACCAGCCCCACCAGCAGCAGCTGTTGATGTTGAAG 
ORF73121PPP123 GACGATCCCGGTCCCGCTGCAGCAAAAAGATACTCCAG 
ORF73134NPS136 AGATACTCCAGGTATCAAAAACCGCATGCTGCAGCTGATCCATTGCCTAAAAAATATCAG 
ORF73141KKY143 AGGTATCAAAAACCGCATAATCCATCTGATCCATTGCCTGCAGCAGCTCAGGGAATGCGAAGACACCT 
ORF73141K ATAATCCATCTGATCCATTGCCTGCAAAATATCAGGGAATGCGAAGAC 
ORF73142K CCATCTGATCCATTGCCTAAAGCATATCAGGGAATGCGAAGAC 
ORF73143Y GCATAATCCATCTGATCCATTGCCTAAAAAAGCTCAGGGAATGCGAAGA 
ORF73138PLP140 TCAAAAACCGCATAATCCATCTGATGCAGCGGCTAAAAAATATCAGGGAATGCGAAG 
 
Table 1. Oligonucleotides designed to generate ORF73 mutants.  
a 
The indicated residues were replaced with alanines. 
4. RESULTS  
4.1. Alanine-scanning mutagenesis: ORF73141KKY143 weakly co-immunoprecipitates 
MYC and p65/RelA  
It has been shown that ORF73 interacts with MYC and p65/RelA through its proline-rich N-
terminal region (amino acid residues 1-140), as observed in co-immunoprecipitation experiments 
(Rodrigues et al., unpublished data). To identify specific amino acid residues in ORF73 that were 
required for binding to MYC and p65/RelA, alanine-scanning mutagenesis was performed in the N-
terminus of ORF73, essentially as described for LANA (Barbera et al., 2006). Alanine-scanning 
mutagenesis is a simple technique that is widely used to determine the functional role of protein 
residues; alanine is the substitution residue of choice because it eliminates the side chains beyond 
the β carbon, without altering the main-chain conformation, or imposing extreme electrostatic or 
steric effects (Cunningham & Wells, 1989; Lefèvre et al., 1997). Potentially, every amino acid in the 
N-terminus of ORF73 could be involved in binding to MYC and p65/RelA. Thus, triple-alanine 
substitutions were introduced at approximately every 10 residues contained within the N-terminus 
of ORF73 (Figure 1). In some cases, the sites of triple substitutions were adjusted, in order to 
include the beginning and the end of the putative nuclear localisation signal (ORF7321KRR23 and 
ORF7335RRR37 mutants), proline-rich regions (ORF7346PPP48 and ORF73121PPP123 mutants) or 
proline/serine-rich regions (ORF7391PPS93 and ORF73134NPS136 mutants). Residues 141-143 were 
not within the region which was previously identified as being important for substrate binding 
(residues 1-140); however, as they were in the neighbourhood, they were still mutated 
(ORF73141KKY143 mutant). Altogether, eleven ORF73 mutants were generated, each one of them 
with only one triple-alanine substitution in its N-terminus.  
The ability of ORF73 mutants to interact with MYC and p65/RelA was then tested by co-
immunoprecipitation experiments. Co-immunoprecipitation is one of the most commonly used 
methods to study protein-protein interactions. This technique allows the isolation of multiprotein 
complexes in a cell lysate, by using an antibody that recognises one of the proteins present in the 
complex (bait protein). Next, Sepharose beads, which are covalently coupled to a protein (e.g. 
protein G) that stably binds to the constant region of the antibody, are added. Thus, the antibody-
bait protein complex will immunoprecipitate. If the bait protein establishes either direct or indirect 
interactions with other proteins in a multiprotein complex, then all the proteins that are part of the 
complex will co-immunoprecipitate. The presence of target proteins can then be assessed by 
Western blotting with the appropriate antibodies, thereby identifying specific protein-protein 
interactions (Masters, 2004). Co-immunoprecipitation experiments with ORF73 mutants and MYC 
or p65/RelA were performed in HEK 293T cells overexpressing either MYC or p65/RelA, and co-
expressing ORF73. The first ten ORF73 mutants (ORF7311TTS13, ORF7321KRR23, ORF7335RRR37, 
ORF7346PPP48, ORF7363PNP65, ORF7376TLP78, ORF7391PPS93, ORF73102SPD104, 
ORF73121PPP123 and ORF73134NPS136) were able to efficiently co-immunoprecipitate MYC and 
p65/RelA. However, the eleventh mutant – ORF73141KKY143 – weakly co-immunoprecipitated both 
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MYC (Figure 2, first panel, lane 4) and p65/RelA (Figure 3, first panel, lane 4), suggesting that 
141KKY143 residues are important for binding of ORF73 to these substrates. Furthermore, it was 
previously shown that, in total cellular lysates, MYC levels are increased in the presence of wild-
type ORF73 (wtORF73), because binding of ORF73 to MYC promotes its stabilization (Rodrigues 
et al., unpublished data). This increase of MYC levels in the presence of wtORF73 was also 
observed in this experiment (Figure 2, third panel, lane 3); however, MYC levels in the presence of 
ORF73141KKY143 (Figure 2, third panel, lane 4) were the same observed in cells not transfected 
with ORF73 protein (Figure 2, third panel, lane 1), which reinforces that 141KKY143 residues are 
important for ORF73 binding to MYC and, consequently, to ORF73 modulatory effect. 
  
Figure 1. Alanine-scanning mutagenesis strategy. The N-terminal region of ORF73 is shown. To identify 
specific amino acid residues in ORF73 that were required for binding to MYC and p65/RelA, triple-alanine 
substitutions were introduced in its N-terminal region. The residues that were replaced with alanines are 
shaded. Eleven ORF73 mutants were generated, each one of them with only one triple-alanine substitution.  
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Figure 2. ORF73
141
KKY
143
 mutant weakly co-immunoprecipitates MYC. HEK 293T cells were transiently 
transfected with plasmids encoding HA-tagged MYC and Myc-tagged ORF73 (either wtORF73 or 
ORF73
141
KKY
143
), as indicated on top. After 48 h, cells were lysed and total cellular lysates were subjected to 
immunoprecipitation using an anti-ORF73 serum. Immunoprecipitates were analysed by Western blotting 
using the indicated antibodies (first and second panels). In addition, representative aliquots of the total cellular 
lysates were used to detect the appropriate expression of MYC (third panel), ORF73 (fourth panel), and actin 
(fifth panel). -, without; +, with; α, anti; IP, immunoprecipitation; TCL, total cellular lysates; WB, Western 
blotting.  
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Figure 3. ORF73
141
KKY
143
 mutant weakly co-immunoprecipitates p65/RelA. HEK 293T cells were 
transiently transfected with plasmids encoding Myc-tagged versions of p65/RelA and ORF73 (either wtORF73 
or ORF73
141
KKY
143
), as indicated on top. After 48 h, cells were lysed and total cellular lysates were subjected 
to immunoprecipitation using an anti-ORF73 serum. Immunoprecipitates were analysed by Western blotting 
using an anti-Myc antibody (first and second panels). In addition, representative aliquots of the total cellular 
lysates were used to detect the appropriate expression of p65/RelA (third panel) and ORF73 (fourth panel).  
-, without; +, with; α, anti; IP, immunoprecipitation; TCL, total cellular lysates; WB, Western blotting.  
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4.2. Mutation at 141KKY143 in ORF73 impairs its ability to activate MYC 
transcriptional activity 
It has been shown that binding of wtORF73 to MYC stabilizes the latter, leading to an 
increase in MYC transcriptional activity in cells transfected with ORF73 (Rodrigues et al., 
unpublished data). ORF73141KKY143 mutant weakly interacted with MYC (Figure 2, first panel, lane 
4), so it was expected that this mutant had impaired ability to activate MYC transcriptional activity. 
To investigate whether ORF73141KKY143 was able to modulate MYC transcriptional activity, reporter 
gene assays were performed, using a MYC reporter plasmid with six tandem repeats of MYC 
consensus sequence (E-box) that drove the expression of firefly luciferase, whose activity was then 
measured. Luciferase activity was correlated with the amount of luciferase produced, which in turn 
depended on the amount of MYC molecules that bound to the consensus sequences, driving 
luciferase expression. Therefore, MYC transcriptional activity could be quantified by measuring 
luciferase activity in each experimental condition. To this end, HEK 293T cells were transiently 
transfected with the MYC reporter plasmid, in the presence or absence of ORF73 (either wtORF73 
or ORF73141KKY143). The experiments were performed either with endogenous levels or 
overexpression of MYC. In experiments with endogenous levels of MYC, cells expressing 
wtORF73 presented a 3,8-fold increase in MYC transcriptional activity (Figure 4, second bar) 
relative to control cells, which did not express ORF73. In contrast, cells expressing 
ORF73141KKY143 showed only a 1,4-fold increase in MYC transcriptional activity (Figure 4, third 
bar), an indication that mutation at 141KKY143 impairs the ability of ORF73 to activate MYC 
transcriptional activity. Since MYC cellular levels are tightly regulated, overexpression of MYC is 
the prototypical positive control for MYC transcriptional activity in reporter assays. Cells not 
expressing ORF73 showed a 8,7-fold increase in MYC transcriptional activity when MYC was 
overexpressed, as expected (Figure 4, fourth bar). Cells expressing wtORF73 exhibited a 42-fold 
increase in MYC transcriptional activity (Figure 4, fifth bar), whereas cells expressing 
ORF73141KKY143 showed only a 19-fold increase (Figure 4, sixth bar), reinforcing that mutation at 
141KKY143 impairs the ability of ORF73 to activate MYC transcriptional activity, both with 
overexpression and with endogenous levels of MYC. 
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Figure 4. ORF73
141
KKY
143
 mutant is unable to efficiently activate MYC transcriptional activity, both 
with endogenous levels and with overexpression of MYC. HEK 293T cells were transiently transfected 
with a MYC luciferase reporter vector, and with plasmids encoding MYC protein and Myc-tagged ORF73 
(either wtORF73 or ORF73
141
KKY
143
), as indicated on bottom. MYC transcriptional activity associated with 
each sample was assayed using a luminometer. Results are shown as the fold induction relative to luciferase 
activity measured in cells with endogenous levels of MYC that did not express ORF73. Error bars represent 
standard deviations of the mean in two independent experiments. In addition, representative aliquots of the 
total cellular lysates were used to detect appropriate expression of ORF73 (bottom panel). -, without; +, with; 
α, anti; WB, Western blotting. 
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4.3. Mutation at 141KKY143 in ORF73 partially impairs its inhibitory effect on NF-kB 
transcriptional activity 
The interaction between wtORF73 and the NF-kB family member p65/RelA leads to the 
inhibition of the transcriptional activity of NF-kB, through proteasomal degradation of nuclear 
p65/RelA (Rodrigues et al., 2009). The interaction between ORF73141KKY143 mutant and p65/RelA 
was weak, since the levels of p65/RelA that co-immunoprecipitated with ORF73141KKY143 were low 
(Figure 3, first panel, lane 4), so it was expected that this mutant could not inhibit NF-kB 
transcriptional activity as efficiently as the wild-type protein. To test this hypothesis, a reporter gene 
assay was performed as described above for MYC. HEK 293T cells were transiently transfected 
with an NF-kB reporter plasmid with three copies of kB consensus sequences that drove the 
expression of firefly luciferase (Winkler et al., 1996), in the presence or absence of ORF73 (either 
wtORF73 or ORF73141KKY143). TNF-α was used as a stimulus leading to NF-kB activation. As in 
MYC reporter assay, NF-kB transcriptional activity could be quantified by measuring luciferase 
activity. In control cells, which did not express ORF73, the luciferase activity increased by 5,4-fold 
in response to TNF (Figure 5, first open bar), meaning that, as expected, NF-kB transcriptional 
activity increases in the presence of a stimulus. In contrast, cells expressing wtORF73 were unable 
to respond effectively to TNF (Figure 5, second open bar), confirming that the viral protein 
abrogates TNF-driven NF-kB activation. On the other hand, cells expressing ORF73141KKY143 
showed a 2,4-fold increase in NF-kB transcriptional activity in response to TNF (Figure 5, third 
open bar), indicating that mutation at 141KKY143 partially impairs the inhibitory effect of ORF73 upon 
NF-kB transcriptional activity. However, ORF73141KKY143 did not completely lose its inhibitory 
effect, since the increase of NF-kB transcriptional activity in cells expressing ORF73141KKY143 was 
lower than in cells not expressing ORF73 at all. This result suggests that although 141KKY143 
residues may be important for ORF73 to bind to p65/RelA, their mutation is not sufficient to 
completely prevent ORF73 inhibitory effect upon NF-kB. Therefore, ORF73141KKY143 mutant 
cannot be used in further studies to investigate the in vivo role of termination of NF-kB 
transcriptional activity by ORF73. However, ORF73141KKY143 mutant was not able to activate MYC 
transcriptional activity (Figure 4, third and sixth bars), so it is a good candidate to clarify the 
biological significance of ORF73-mediated MYC activation.  
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Figure 5. ORF73
141
KKY
143
 mutant has partially impaired ability to inhibit TNF-driven NF-kB 
transcriptional activity. HEK 293T cells were transiently transfected with an NF-kB luciferase reporter vector 
and a plasmid encoding Myc-tagged ORF73 (either wtORF73 or ORF73
141
KKY
143
), as indicated on bottom. 
Transfected cells were either stimulated with 50 ng/ml of TNF (open bars) or left unstimulated (filled bars). NF-
kB transcriptional activity associated with each sample was assayed using a luminometer. Results are 
shown as the fold induction relative to luciferase activity measured in unstimulated cells. Error bars 
represent standard deviations of the mean in two independent experiments. In addition, representative 
aliquots of the total cellular lysates were used to detect the appropriate expression of ORF73 (bottom panel).  
-, without; +, with; α, anti; WB, Western blotting.  
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4.4. Mutation at 141KKY143 in ORF73 does not affect its nuclear localisation 
ORF73 has a putative nuclear localisation signal (NLS) in residues 21 to 37 
(KRRCFNKPAAMPPKRRR) (Figure 1), so it localises primarily to the nucleus when transiently 
expressed in HEK 293T cells, as assessed by immunofluorescence (Rodrigues et al., 2009). 
Although the mutations introduced in ORF73141KKY143 were not in the NLS, they could modify the 
global structure of the protein in such a way that the NLS was masked. To analyse whether the 
introduced mutations affected the subcellular localisation of ORF73, HEK 293T cells were 
transiently transfected with either wtORF73 or ORF73141KKY143, and immunofluorescence 
experiments were performed. Results showed that, similarly to wtORF73, ORF73141KKY143 
localises to the nucleus of transfected cells (Figure 6, panel f). 
  
Figure 6. ORF73
141
KKY
143 
localises to the nucleus. HEK 293T cells were transiently transfected with a 
plasmid encoding Myc-tagged wtORF73 (panels a, b and c) or ORF73
141
KKY
143 
(panels d, e and f). After 24 h, 
cells were fixed and subjected to immunostaining with anti-Myc antibody, followed by incubation with Alexa 
594 anti-mouse secondary antibody (red). Nuclear DNA was stained with DAPI solution (blue) to visualize the 
nucleus.  
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4.5. Mutation at 138PLP140 in ORF73 partially impairs its ability to co-
immunoprecipitate MYC 
ORF73141KKY143 protein had three mutated amino acid residues; however, it was possible that 
a mutation in a single residue was enough to lose MYC binding. If this hypothesis was true, then a 
mutant ORF73 protein with only one mutated residue could be used in further experiments, 
decreasing the probability that the introduced mutation modified the global structure of the protein, 
since a smaller number of original residues were mutated. Therefore, to assess if single mutations 
at 141KKY143 residues had the same effect that the triple mutation upon the ability of ORF73 to bind 
to MYC, single-alanine substitutions were introduced at 141K, 142K, and 143Y residues, generating 
ORF73141K, ORF73142K, and ORF73143Y mutants, respectively (Figure 7). 138PLP140 residues were 
adjacent to 141KKY143 residues, and they were contained within the region that was previously 
identified as being important for MYC binding (residues 1-140; Rodrigues et al., unpublished data). 
To test if these residues also had a role in MYC binding, a mutant with a triple-alanine substitution 
at 138PLP140 residues was generated (Figure 7). The ability of ORF73141K, ORF73142K, ORF73143Y 
and ORF73138PLP140 mutants to interact with MYC was then tested by co-immunoprecipitation 
experiments, in HEK 293T cells overexpressing MYC and co-expressing ORF73 (either wild-type 
or mutants). ORF73141K and ORF73143Y (Figure 8, first panel, lanes 4 and 6, respectively) co-
immunoprecipitated MYC as efficiently as wtORF73 (Figure 8, first panel, lane 2); in contrast, the 
levels of MYC that co-immunoprecipitated with ORF73142K (Figure 8, first panel, lane 5) were lower 
than the levels with wtORF73, but higher than with ORF73141KKY143 (Figure 8, first panel, lane 3). 
Accordingly, MYC levels in total cellular lysates were increased in the presence of ORF73141K, 
ORF73142K, and ORF73143Y mutants (Figure 8, third panel, lanes 4, 5 and 6, respectively), relative 
to MYC levels in cells not transfected with ORF73 protein (Figure 8, third panel, lane 1). This result 
indicated that triple-alanine substitution at 141KKY143 residues caused a more severe deficit in the 
ability of ORF73 to bind to MYC than each of the single-alanine substitutions. Therefore, there was 
no advantage in using single mutants instead of the ORF73141KKY143 triple mutant to study the role 
of ORF73-MYC interaction, so ORF73141KKY143 was the mutant used in further experiments. As far 
as ORF73138PLP140 mutant is concerned, it co-immunoprecipitated lower levels of MYC (Figure 8, 
first panel, lane 7) than wtORF73 (Figure 8, first panel, lane 2), but higher levels of MYC than 
ORF73141KKY143 (Figure 8, first panel, lane 3). This suggests that 138PLP140 residues are important 
for binding of ORF73 to MYC. 
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Figure 7. Alanine-scanning mutagenesis strategy (second screening). The N-terminal region of ORF73 is 
shown. The residues that were replaced with alanines are shaded.  
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Figure 8. ORF73
138
PLP
140
 mutant has impaired ability to co-immunoprecipitate MYC. HEK 293T cells 
were transiently transfected with plasmids encoding HA-tagged MYC and Myc-tagged ORF73 (either wild-type 
or mutants), as indicated on top. After 48 h, cells were lysed and total cellular lysates were subjected to 
immunoprecipitation using an anti-ORF73 serum. Immunoprecipitates were analysed by Western blotting 
using the indicated antibodies (first and second panels). In addition, representative aliquots of the total cellular 
lysates were used to detect the appropriate expression of MYC (third panel), ORF73 (fourth panel), and actin 
(fifth panel). -, without; +, with; α, anti; IP, immunoprecipitation; TCL, total cellular lysates; WB, Western 
blotting.  
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4.6. Mutation at 138PLP140 in ORF73 impairs its ability to activate MYC transcriptional 
activity 
To test the ability of ORF73138PLP140 triple mutant to activate MYC transcriptional activity, a 
reporter gene assay was performed as described above for ORF73141KKY143 mutant. MYC reporter 
assays with ORF73141KKY143 mutant (Figure 4) showed that the pattern of MYC transcriptional 
activity was similar in the presence of endogenous levels of MYC and in the presence of 
overexpressed MYC. Therefore, and since the system with endogenous levels of MYC better 
mimics the physiological condition in cells, the reporter assay with ORF73138PLP140 mutant was 
performed with endogenous MYC only. In this experiment, cells expressing wtORF73 exhibited a 
91-fold increase in MYC transcriptional activity (Figure 9, second bar) in comparison to control 
cells, which did not express ORF73 (Figure 9, first bar). On the other hand, cells expressing 
ORF73138PLP140 presented a 5,8-fold increase in MYC transcriptional activity (Figure 9, fourth bar), 
slightly more than the 2,4-fold increase in cells expressing ORF73141KKY143 (Figure 9, third bar). 
This result indicates that mutation at 138PLP140 residues impairs the ability of ORF73 to activate 
MYC transcriptional activity, although this impairment is not as strong as the one observed when 
141KKY143 residues are mutated.  
To confirm the results obtained in co-immunoprecipitation experiments with MYC and ORF73 
single mutants, these mutants were also included in the reporter gene assay. The single mutants 
used in this experiment were ORF73142K, since it showed some impairment in the ability to co-
immunoprecipitate MYC (Figure 8, first panel, lane 5), and ORF73141K, as a representative of the 
single mutants that co-immunoprecipitated MYC as efficiently as wtORF73. As ORF73141K mutant 
behaved the same way that ORF73143Y mutant in the co-immunoprecipitation experiment (Figure 
8, first panel, lanes 4 and 6, respectively), ORF73143Y was not included in this reporter assay, and 
it was assumed that the results obtained for ORF73141K mutant in this experiment were the same 
for ORF73143Y mutant. Reporter assay results showed that the transcriptional activity of MYC 
increased by 58-fold in the presence of ORF73142K (Figure 9, sixth bar), a level between MYC fold 
increase in the presence of wtORF73 (91-fold increase; Figure 9, second bar) and ORF73141KKY143 
(2,4-fold increase, Figure 9; third bar). This was in good agreement with the result obtained in the 
co-immunoprecipitation, since ORF73142K mutant co-immunoprecipitated lower levels of MYC than 
wtORF73, but higher levels than ORF73141KKY143. Furthermore, cells expressing ORF73141K 
showed a 110-fold increase in MYC transcriptional activity (Figure 9, fifth bar), a level even higher 
than the observed in cells expressing wtORF73 (Figure 9, second bar). Therefore, this reporter 
assay confirmed that there was no advantage in using single mutants instead of the 
ORF73141KKY143 triple mutant to study the role of ORF73-MYC interaction, since triple-alanine 
substitution at 141KKY143 residues caused a more severe impairment in the ability of ORF73 to 
activate MYC transcriptional activity than each of the single-alanine substitutions.  
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Figure 9. ORF73
138
PLP
140
 mutant is unable to efficiently activate MYC transcriptional activity. HEK 
293T cells were transiently transfected with a MYC luciferase reporter vector and a plasmid encoding Myc-
tagged ORF73 (either wild-type or mutants), as indicated on bottom. MYC transcriptional activity associated 
with each sample was assayed using a luminometer. Results are shown as the fold induction relative to 
luciferase activity measured in cells that did not express ORF73. Error bars represent standard 
deviations of the mean of triplicates. In addition, representative aliquots of the total cellular lysates were used 
to detect the appropriate expression of ORF73 (bottom panel). -, without; +, with; α, anti; WB, Western 
blotting.  
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4.7. Mutation at 138PLP140 in ORF73 does not affect its ability to co-
immunoprecipitate p65/RelA  
Next, the ability of ORF73138PLP140 mutant to interact with p65/RelA was tested by co-
immunoprecipitation, in HEK 293T cells overexpressing p65/RelA and co-expressing ORF73 
(either wild-type or mutants). ORF73138PLP140 mutant (Figure 10, first panel, lane 4) co-
immunoprecipitated p65/RelA approximately as efficiently as wtORF73 (Figure 10, first panel, lane 
2). This suggests that 138PLP140 residues are not involved in binding of ORF73 to p65/RelA, 
although they may have a role in binding to MYC (Figure 8, first panel, lane 7). Therefore, it was 
expected that mutation at 138PLP140 residues did not affect ORF73 inhibitory effect towards NF-kB.  
  
Figure 10. ORF73
138
PLP
140
 mutant efficiently co-immunoprecipitates p65/RelA. HEK 293T cells were 
transiently transfected with plasmids encoding p65/RelA and Myc-tagged ORF73 (either wild-type or mutants), 
as indicated on top. After 48 h, cells were lysed and total cellular lysates were subjected to 
immunoprecipitation using an anti-ORF73 serum. Immunoprecipitates were analysed by Western blotting 
using the indicated antibodies (first and second panels). In addition, representative aliquots of the total cellular 
lysates were used to detect the appropriate expression of p65/RelA (third panel) and ORF73 (fourth panel). 
 -, without; +, with; α, anti; IP, immunoprecipitation; TCL, total cellular lysates; WB, Western blotting.  
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4.8. Mutation at 138PLP140 in ORF73 partially impairs its inhibitory effect on NF-kB 
transcriptional activity 
To assess whether ORF73138PLP140 mutant maintained its ability to modulate NF-kB 
transcriptional activity, a reporter gene assay was performed as described above for 
ORF73141KKY143 mutant. In control cells, which did not express ORF73, the luciferase activity 
increased by 6,1-fold in response to TNF (Figure 11, first open bar). As observed before, cells 
expressing wtORF73 were unable to respond effectively to TNF (Figure 11, second open bar). In 
contrast, cells expressing ORF73138PLP140 showed a 3,3-fold increase in NF-kB transcriptional 
activity in response to TNF (Figure 11, fourth open bar), indicating that mutation at 138PLP140 
residues causes some impairment in the inhibitory effect of ORF73 upon NF-kB. Thus, although 
ORF73138PLP140 mutant co-immunoprecipitated p65/RelA as efficiently as wtORF73 (Figure 10, 
first panel, compare lanes 2 and 4), it lost the ability exhibited by the wild-type protein to completely 
inhibit NF-kB transcriptional activity.  
  
Figure 11. ORF73
138
PLP
140
 mutant has partially impaired ability to inhibit TNF-driven NF-kB 
transcriptional activity. HEK 293T cells were transiently transfected with an NF-kB luciferase reporter vector 
and a plasmid encoding Myc-tagged ORF73 (either wtORF73, ORF73
141
KKY
143 
or ORF73
138
PLP
140
), as 
indicated on bottom. Transfected cells were either stimulated with 50 ng/ml of TNF (open bars) or left 
unstimulated (filled bars). NF-kB transcriptional activity associated with each sample was assayed using a 
luminometer. Results are shown as the fold induction relative to luciferase activity measured in 
unstimulated cells. Error bars represent standard deviations of the mean of triplicates. In addition, 
representative aliquots of the total cellular lysates were used to detect the appropriate expression of ORF73 
(bottom panel). -, without; +, with; α, anti; WB, Western blotting.  
28 
 
4.9. Mutation at 141KKY143 or 138PLP140 in ORF73 compromises its ability to promote 
MYC and p65/RelA poly-ubiquitination 
wtORF73 modulates MYC and NF-kB transcriptional activity through poly-ubiquitination of 
these substrates. ORF73-mediated poly-ubiquitination of MYC stabilizes it (Rodrigues et al., 
unpublished data). In contrast, ORF73-mediated poly-ubiquitination of p65/RelA leads to its 
proteasomal-dependent degradation (Rodrigues et al., 2009). ORF73141KKY143 mutant weakly co-
immunoprecipitated both MYC (Figure 2, first panel, lane 4) and p65/RelA (Figure 3, first panel, 
lane 4), suggesting that it weakly interacted with these substrates. Moreover, ORF73138PLP140 
mutant exhibited a deficit in its ability to co-immunoprecipitate MYC (Figure 8, first panel, lane 7), 
indicating that this mutant had impaired ability to interact with MYC. As ORF73 functions as an E3 
ubiquitin-ligase, and the poly-ubiquitination mediated by E3 ubiquitin-ligase complexes depends on 
the interaction of complexes with their substrates, a poly-ubiquitination assay was performed to 
investigate whether ORF73141KKY143 and ORF73138PLP140 mutants were capable of targeting MYC 
and p65/RelA for poly-ubiquitination. In this experiment, HEK 293T cells were co-transfected with 
His-tagged ubiquitin and either MYC or p65/RelA, in the presence or absence of ORF73 
(wtORF73, ORF73141KKY143, or ORF73138PLP140), and the corresponding total cellular lysates were 
subjected to a nickel-nitrilotriacetic acid (Ni-NTA) pull-down. Since His-tagged ubiquitin was 
incorporated in the poly-ubiquitin chains, poly-ubiquitinated proteins were His-tagged. Ni-NTA 
beads had high affinity for His-tagged proteins, allowing their purification from an expression 
system. Therefore, poly-ubiquitinated MYC and p65/RelA were pulled down by Ni-NTA beads, and 
then detected by Western blotting with the appropriate antibodies. Results showed that both 
ORF73141KKY143 and ORF73138PLP140 mutants only poorly enhanced the poly-ubiquitination of 
MYC, in comparison with wtORF73 protein (Figure 12, first panel, compare lanes 2, 3 and 4). 
Similarly, neither ORF73141KKY143 nor ORF73138PLP140 could promote the poly-ubiquitination of 
p65/RelA as efficiently as the wtORF73 (Figure 13, first panel, compare lanes 2, 3 and 4). Thus, 
both ORF73141KKY143 and ORF73138PLP140 mutants were deficient in MYC and p65/RelA poly-
ubiquitination, reinforcing that 141KKY143 and 138PLP140 residues are important for ORF73-mediated 
modulation of MYC and p65/RelA. 
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Figure 12. ORF73
141
KKY
143
 and ORF73
138
PLP
140
 mutants are unable to efficiently promote MYC poly-
ubiquitination. HEK 293T cells were transiently transfected with plasmids encoding HA-tagged MYC, Myc-
tagged ORF73 and histidine-tagged ubiquitin, as indicated on top. After 48 h, cells were lysed and total 
cellular lysates were subjected to a Ni-NTA pull-down, allowing the purification of ubiquitinated proteins. The 
levels of poly-ubiquitinated MYC in each condition were assayed using an anti-HA antibody (first panel). In 
addition, representative aliquots of the total cellular lysates were used to detect the appropriate expression of 
MYC (second panel) and ORF73 (third panel). -, without; +, with; α, anti; PD, pull-down; TCL, total cellular 
lysates; WB, Western blotting.  
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Figure 13. ORF73
141
KKY
143
 and ORF73
138
PLP
140
 mutants are unable to efficiently promote p65/RelA 
poly-ubiquitination. HEK 293T cells were transiently transfected with plasmids encoding p65/RelA, Myc-
tagged ORF73 and histidine-tagged ubiquitin, as indicated on top. After 48 h, cells were lysed and total 
cellular lysates were subjected to a Ni-NTA pull-down, allowing the purification of ubiquitinated proteins. The 
levels of poly-ubiquitinated p65/RelA in each condition were assayed using an anti-p65 antibody (first panel). 
In addition, representative aliquots of the total cellular lysates were used to detect the appropriate expression 
of p65/RelA (second panel) and ORF73 (third panel). -, without; +, with; α, anti; PD, pull-down; TCL, total 
cellular lysates; WB, Western blotting.  
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4.10. Mutation at 141KKY143 or 138PLP140 in ORF73 compromises its ability to 
assemble an E3 ubiquitin-ligase complex 
Rodrigues et al. have shown that the ability of wtORF73 to promote the substrate poly-
ubiquitination relies on the reconstitution of an E3 ubiquitin-ligase complex. wtORF73 recruits 
ElonginC and Cullin5 through its SOCS-box motif (residues 199-215), and thereby assembles an 
EC5S
ORF73 
complex (Rodrigues et al., 2009). As the alanine substitutions of ORF73141KKY143 and 
ORF73138PLP140 mutants were not introduced at the SOCS-box, it was expected that these mutants 
maintained the ability to interact with ElonginC and Cullin5, despite being deficient in MYC and 
p65/RelA binding. To test whether ORF73141KKY143 and ORF73138PLP140 could associate with 
ElonginC and Cullin5, co-immunoprecipitation experiments were performed in HEK 293T cells 
overexpressing ElonginC or Cullin5, and co-expressing either the wild-type or mutant versions of 
ORF73 protein. As expected, wtORF73 strongly co-immunoprecipitated both with ElonginC (Figure 
14, first panel, lane 2) and Cullin5 (Figure 15, first panel, lane 2). Surprisingly, only low levels of 
ORF73141KKY143 and ORF73138PLP140 mutants co-immunoprecipitated with ElonginC (Figure 14, 
first panel, lanes 3 and 4, respectively). However, both mutants co-immunoprecipitated well with 
Cullin5 (Figure 15, first panel, lanes 3 and 4, respectively), suggesting that the interaction with this 
component of the EC5S
ORF73 
complex was not affected. These results indicate that although 
ORF73141KKY143 and ORF73138PLP140 mutants do not have mutations at their SOCS-box, they are 
unable to efficiently recruit ElonginC. Therefore, ORF73141KKY143 and ORF73138PLP140 mutants do 
not assemble all the components of the EC5S
ORF73 
ubiquitin-ligase complex, and consequently they 
cannot promote the substrate poly-ubiquitination. The fact that ORF73141KKY143 and 
ORF73138PLP140 mutants showed compromised E3 ubiquitin-ligase activity, despite they did not 
have a mutated SOCS-box, suggests that the mutations that were introduced at either 141KKY143 or 
at 138PLP140 residues altered the three dimensional structure of ORF73, in a way that the SOCS-
box was affected and the interaction with ElonginC was compromised.  
The inability of ORF73138PLP140 mutant to properly assemble the EC5S
ORF73 
ubiquitin-ligase 
complex can account for the discrepancies that were found between co-immunoprecipitation 
experiments and reporter assays with this mutant. Since ORF73138PLP140 did not have E3 ubiquitin-
ligase activity, it could not promote MYC poly-ubiquitination. Therefore, MYC was not stabilized 
and, consequently, its transcriptional activity did not increase in the presence of ORF73138PLP140. 
This explains the results obtained in the reporter assay, where ORF73138PLP140 and 
ORF73141KKY143 mutants showed a similar deficit in the ability to activate MYC transcriptional 
activity (Figure 9, compare third and fourth bars), although ORF73138PLP140 co-immunoprecipitated 
higher levels of MYC than ORF73141KKY143, in co-immunoprecipitation experiments (Figure 8, first 
panel, compare lanes 3 and 7). Similarly, since ORF73138PLP140 mutant co-immunoprecipitated 
p65/RelA as efficiently as wtORF73 (Figure 10, first panel, compare lanes 2 and 4), it was 
expected that NF-kB transcriptional activity was completely inhibited in the presence of 
ORF73138PLP140, as it was observed in the presence of wtORF73. However, the reporter assay 
showed that this mutant had an impaired ability to inhibit NF-kB (Figure 11, fourth bar). This result 
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can now be explained taking into account that ORF73138PLP140 did not have E3 ubiquitin-ligase 
activity, so it could not promote p65/RelA poly-ubiquitination and its subsequent degradation.  
  
Figure 14. ORF73
141
KKY
143
 and ORF73
138
PLP
140
 mutants are unable to recruit ElonginC. HEK 293T cells 
were transiently transfected with plasmids encoding Flag-tagged ElonginC and Myc-tagged ORF73 (either 
wild-type or mutants), as indicated on top. After 48 h, cells were lysed and total cellular lysates were subjected 
to immunoprecipitation using an anti-ElonginC antibody. Immunoprecipitates were analysed by Western 
blotting using the indicated antibodies (first and second panels). In addition, representative aliquots of the total 
cellular lysates were used to detect the appropriate expression of ORF73 (third panel), ElonginC (fourth 
panel), and actin (fifth panel). -, without; +, with; α, anti; EloC, ElonginC; IP, immunoprecipitation; TCL, total 
cellular lysates; WB, Western blotting.  
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Figure 15. ORF73
141
KKY
143
 and ORF73
138
PLP
140
 mutants maintain the ability to recruit Cullin5. HEK 
293T cells were transiently transfected with plasmids encoding Myc-tagged versions of Cullin5 and ORF73 
(either wild-type or mutants), as indicated on top. After 48 h, cells were lysed and total cellular lysates were 
subjected to immunoprecipitation using an anti-Cullin5 antibody. Immunoprecipitates were analysed by 
Western blotting using the indicated antibodies (first and second panels). In addition, representative aliquots 
of the total cellular lysates were used to detect the appropriate expression of ORF73 (third panel) and Cullin5 
(fourth panel). -, without; +, with; α, anti; Cul5, Cullin5; IP, immunoprecipitation; TCL, total cellular lysates; WB, 
Western blotting.  
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5. DISCUSSION 
During this project, two ORF73 mutants with impaired ability to interact with MYC and 
p65/RelA were identified – ORF73141KKY143 and ORF73138PLP140 mutants. Both mutants were 
unable to efficiently activate MYC transcriptional activity, and their inhibitory effect upon NF-kB 
transcriptional activity was partially impaired. Moreover, they were unable to promote strong MYC 
and p65/RelA poly-ubiquitination. Nonetheless, and despite recruiting Cullin5, both mutants were 
unable to efficiently recruit ElonginC, thereby compromising the assembly of EC5S
ORF73
 ubiquitin-
ligase complex and the ORF73-mediated poly-ubiquitination of substrates. Consequently, 
ORF73141KKY143 and ORF73138PLP140 mutants are not useful in the study of the biological role of 
ORF73 modulatory function towards MYC and NF-kB, as will be discussed next.  
First, as these mutants have compromised E3 ubiquitin-ligase activity, they are unable to 
properly modulate MYC and NF-kB, as well as other cellular substrates that are possibly being 
modulated by ORF73 and remain to be identified. Thus, ORF73141KKY143 and ORF73138PLP140 
recombinant viruses will exhibit a phenotype equivalent to ORF73-SOCS mutant, which was 
previously described (Rodrigues et al., 2009). Therefore, the use of ORF73141KKY143 and 
ORF73138PLP140 mutants in in vivo studies will not contribute to clarify the independent role of the 
modulation of MYC and NF-kB during MuHV-4 latent infection.  
Second, the fact that ORF73141KKY143 and ORF73138PLP140 mutants do not have mutations at 
their SOCS-box, and still they are unable to efficiently recruit ElonginC, indicates that mutations at 
141KKY143 or 138PLP140 residues may have a severe impact in the three dimensional structure of 
ORF73, compromising its functionality. Therefore, not only the E3 ubiquitin-ligase activity of ORF73 
is disrupted, but also its putative role as a viral episome maintenance protein may be affected. 
Furthermore, it is possible that the fact that ORF73141KKY143 and ORF73138PLP140 mutants have a 
disrupted three dimensional structure accounts for the loss of binding of these mutants to MYC and 
p65/RelA.  
Since neither ORF73141KKY143 nor ORF73138PLP140 mutants can be used in further 
experiments to investigate the role of ORF73-mediated modulation of MYC and NF-kB, other 
strategies must be developed in order to identify MYC and p65/RelA binding motifs in ORF73, 
thereby allowing the construction of ORF73 mutants that maintain E3 ubiquitin-ligase activity but 
are unable to modulate MYC and NF-kB, separately. The determination of the three dimensional 
structure of ORF73, which remains unresolved, may shed light on the amino acid residues that can 
be mutated by alanine-scanning mutagenesis to obtain those ORF73 mutants. Thus far, it is known 
that the C-terminus of ORF73 is important for oligomerization with other ORF73 molecules (Pires 
de Miranda et al., unpublished data). Furthermore, the alignment of ORF73 with LANA and 
Epstein-Barr virus nuclear antigen 1 (EBNA1), the latency-associated proteins of KSHV and EBV 
viruses, respectively, shows that ORF73 shares some sequence homology with KSHV and EBNA1 
between its amino acid residues 141 and 250, which are predicted to form α-helixes and β-sheets 
(Figure 16). Since the homologous region in EBNA1 (residues 470-607) is a DNA-binding region 
(Bochkarev et al., 1995), it is also thought that 141-250 residues in ORF73 are involved in DNA 
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binding. In contrast, no secondary structure is predicted for the N-terminus of ORF73 (residues 1-
140), which has been associated with MYC and p65/RelA interaction (Rodrigues et al., unpublished 
data). Several studies have shown that the existence of disordered regions in proteins allows them 
to bind to many different partners, using the same or different interfaces, since disordered regions 
can acquire different conformations depending on the partners they are bound to (Fong et al., 
2009). Thus, the fact that the N-terminus of ORF73 is a disordered region reinforces the role of this 
portion of the protein in the interaction with MYC and p65/RelA. Understanding the spatial 
disposition of secondary structures and disordered regions in ORF73, and the way these regions 
come close together, will probably reveal narrower regions within the N-terminus that interact with 
MYC or p65/RelA. Therefore, the resolution of the three dimensional structure of ORF73, by 
crystallography techniques, may be an important tool to restrict the residues to be mutated by 
alanine-scanning mutagenesis without compromising the global structure of the viral protein, 
allowing a more accurate choice of the residues to be tested. Furthermore, co-crystallization 
studies with ORF73 and MYC, or ORF73 and p65/RelA, may also allow the identification of 
substrate binding motifs in ORF73. 
 
 
 
 
 
  
Figure 16. High structural similarity between C-terminal ORF73, LANA and EBNA1. Structure based 
sequence alignment of ORF73 and LANA. Phyre server generated alignment based on EBNA1 structure 
(PDB code: 1vhi). Red highlights, conserved residues; yellow highlights, semi-conserved residues. Predicted 
secondary structure is shown on top of alignment, whereas actual secondary structure of EBNA1 is shown 
below the alignment. α, α-helix; β, β-sheet; η, helix turn; TT, beta turn. (Pires de Miranda et al., unpublished 
data). 
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6. CONCLUSION  
This work allowed the exclusion of some amino acid residues in ORF73 viral protein as 
possible MYC or p65/RelA substrate binding motifs. Mutation at 141KKY143 or 138PLP140 residues in 
ORF73 impaired its ability to interact and modulate MYC and p65/RelA, but also compromised its 
E3 ubiquitin-ligase activity. Consequently, ORF73141KKY143 and ORF73138PLP140 mutants did not 
prove to be useful in future experiments. Hence, MYC and p65/RelA binding-deficient ORF73 
mutants that retain E3 ubiquitin-ligase and episome maintenance functions are needed, so this 
work must be continued and other approaches must be exploited. Therefore, recombinant viruses 
with disrupted ability to modulate MYC or NF-kB can be constructed, and the biological significance 
of ORF73 modulatory function towards each one of these cellular targets during MuHV-4 latent 
infection can be finally enlightened.  The results of such experiments may give an important 
contribute to understand the role of LANA E3 ubiquitin-ligase activity in KSHV latency.  
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